Poly-ICLC (Hiltonol) Plus Anti-PD1 or Anti-PD-L1 in Unresectable Solid Cancers An Adaptive Phase I/II Clinical Pilot Study
Phase of Trial: Phase I/II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Poly ICLC (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Sponsors Oncovir
- 30 Oct 2019 Planned End Date changed from 31 Aug 2022 to 31 Aug 2023.
- 30 Oct 2019 Planned primary completion date changed from 31 Aug 2020 to 31 Aug 2021.
- 02 Nov 2018 New trial record